Patents by Inventor Jeong Su Jang

Jeong Su Jang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11935984
    Abstract: A quantum dot including a core that includes a first semiconductor nanocrystal including zinc and selenium, and optionally sulfur and/or tellurium, and a shell that includes a second semiconductor nanocrystal including zinc, and at least one of sulfur or selenium is disclosed. The quantum dot has an average particle diameter of greater than or equal to about 13 nm, an emission peak wavelength in a range of about 440 nm to about 470 nm, and a full width at half maximum (FWHM) of an emission wavelength of less than about 25 nm. A method for preparing the quantum dot, a quantum dot-polymer composite including the quantum dot, and an electronic device including the quantum dot is also disclosed.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: March 19, 2024
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Yong Seok Han, Sung Woo Kim, Jin A Kim, Tae Hyung Kim, Kun Su Park, Yuho Won, Jeong Hee Lee, Eun Joo Jang, Hyo Sook Jang
  • Publication number: 20190167026
    Abstract: A juicer including: a driving part composed of a housing having a housing hollow part formed therein, and having a through-hole through which inner air is discharged at the position eccentric to one side in the width direction from the central portion formed on the bottom portion thereof, and a motor provided the housing hollow part by being surrounded by a motor housing; a juice part connected to the driving part to be driven to squeeze the juice; and a fastening part for detachably coupling the juice part to the driving part.
    Type: Application
    Filed: August 29, 2017
    Publication date: June 6, 2019
    Applicant: ANGEL CO., LTD.
    Inventors: Mun Hyun LEE, Chom Tu I KIM, Mong Ryong LEE, Jin Woo SON, Han Sung YANG, Jeong Su JANG, Seong-hwan PARK, Na Hyun KWON, Eun Hui JI, Min Ji KIM, Hye-Jung PARK
  • Patent number: 9413219
    Abstract: Disclosed is a system for controlling a power-up sequence applicable to a power controller of a lane departure warning system, including: one DC/DC converter unit configured to convert a first input voltage of input power and output the converted first input voltage as a first output voltage, and including four output terminals; and a comparator block unit including two comparators configured to monitor a state of the input power, and one or more comparators configured to generate a control signal for enabling a power output of a next sequence from the first output voltage.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: August 9, 2016
    Assignee: Hyundai Mobis Co., Ltd.
    Inventor: Jeong Su Jang
  • Publication number: 20150123639
    Abstract: Disclosed is a system for controlling a power-up sequence applicable to a power controller of a lane departure warning system, including: one DC/DC converter unit configured to convert a first input voltage of input power and output the converted first input voltage as a first output voltage, and including four output terminals; and a comparator block unit including two comparators configured to monitor a state of the input power, and one or more comparators configured to generate a control signal for enabling a power output of a next sequence from the first output voltage.
    Type: Application
    Filed: May 1, 2014
    Publication date: May 7, 2015
    Applicant: HYUNDAI MOBIS CO., LTD.
    Inventor: Jeong Su Jang
  • Publication number: 20100233192
    Abstract: Disclosed is a method for preparing activated lymphocytes, which comprises isolating lymphocytes from peripheral blood and proliferating and activating the isolated lymphocytes in vitro. According to the disclosed method, highly effective toxic cells can be prepared in large amounts by culturing human peripheral lymphocytes in the presence of an anti-CD3 antibody, IFN-? and IL-2. The activated lymphocytes proliferated according to the disclosed preparation method comprise both CD3-CD56+ (natural killer cell marker) cells that are the main components of LAK cells, and CD3+CD56+ cells that are the main components of CIK cells, and can be cultured in large amounts. Thus, the lymphocyte cells can show a significantly higher anticancer effect compared to when the LAK cells and the CIK cells are used alone.
    Type: Application
    Filed: April 18, 2007
    Publication date: September 16, 2010
    Applicant: Binex Co., Ltd.
    Inventors: Soon Won Park, Young Ok Son, Cheol Hun Son, You Soo Park, Jung Hwa Ban, Kyoung-Gyu Lee, Jeong Su Jang, Chi Dug Kang, Won-Suk Kim, Kyung Chool An, Back Chun Lee, Ju In Kim, Eun Kyung Park, Sung Hee Choi